Skip to Content
Merck
All Photos(1)

Documents

14380C

SAFC

EX-CELL® CD Insect Cell Medium

Chemically defined, sterile-filtered, suitable (for insect cell culture)

Pharma Manufacturing

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352200

Quality Level

sterility

sterile-filtered

form

liquid

technique(s)

cell culture | insect: suitable

components

NaHCO3: no
L-glutamine: yes

shipped in

ambient

storage temp.

2-8°C

General description

EX-CELL® CD Insect Cell Medium can be used as amplification and production medium for Spodoptera frugiperda (Sf) cells such as Sf21 and Sf9 cells and is compatible with Tni, C636 and S2 cells. The medium has been optimized to get excellent growth and productivity for the rhabdovirus-free Sf-RVN Insect Cell Line(Sf9). Together those products form the Sf-RVN Platform. The formulation is chemically defined, animal-component free and has been formulated with L-Glutamine.

Legal Information

EX-CELL is a registered trademark of Merck KGaA, Darmstadt, Germany
Sf-RVN is a trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Articles

Optimizing the upstream portion of gene therapy production sets the stage for successful manufacturing by maximizing viral vector titers. To increase upstream titers and process productivity, manufacturers must partner with upstream technology experts who work with HEK293, HEK293T and Sf9 cells. Draw on our experience today to speed your gene therapy to patients.

This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.

Related Content

The new Sf-RVN® Platform provides a high performant rhabdovirus-free alternative to produce recombinant proteins, virus-like particles (VLP) for viral vaccines, and adeno-associated viruses (AAV) to treat genetic diseases, improving the safety profile of your gene therapy and vaccines.

A transfection-based solution to viral vector production using a suspension cell line, chemically defined medium, and a process with proven performance at scale.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service